Accessibility Tools

GeoVax Recent News

GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress

Dr. Diamond and City of Hope COVID-19 Vaccine Team Nominated for Best Academic/Research Team Award

Atlanta, GA, March 15, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against solid tumor cancers and infectious diseases, today congratulates its colleague and collaborator, Don Diamond, Ph.D. for recognition as a finalist for the Best Academic/Research Team Award, part of the Vaccine Industry Excellence (ViE) Awards to be held during the World Vaccine Congress in Washington, DC on April 3-6, 2023.

“Dr. Diamond and his team well-deserve this award and we are proud to be collaborating with Don and his colleagues on the clinical development of our next-generation COVID-19 vaccine candidate, GEO-CM04S1,” stated David Dodd, GeoVax’s Chairman and CEO. “GEO-CM04S1 resulted from research and development conducted at City of Hope under Dr. Diamond’s leadership and is now a GeoVax priority development program, progressing in two ongoing Phase 2 clinical trials. We applaud the foresight reflected in the development of GEO-CM04S1 and look forward to the further acceleration of the clinical program as it continues to expand to multiple sites with interest worldwide.”

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

 

Investor Relations Contact:

Rich Cockrell

CG Capital

404-736-3838

This email address is being protected from spambots. You need JavaScript enabled to view it.

Authors

GeoVax

SUBSCRIBE FOR UPDATES FROM GEOVAX
Register to receive email alerts for GeoVax press releases
Copyright © GeoVax 2024. All Rights Reserved.

Search